relative to product labeling and information guide requirements for cannabis products and the prohibition of the sale of hemp products containing certain levels of THC.

This bill requires therapeutic cannabis oversight boards to develop and update product labels and educational materials regarding cannabis risks for qualifying patients. It also prohibits the sale of hemp-derived products that contain more than 0.03% THC, including specific variants like delta-8 and delta-9. The changes apply to alternative treatment centers and certifying medical providers, with the law taking effect 60 days after passage.